Overall, identification of ERβ+ TN breast tumors, in combination with the use of ERβ-targeted therapies, has the potential to improve the outcomes of a proportion of TNBC patients for whom treatment options are currently limited. This evidence concerns the gene ESR2 and breast neoplasm.